FDA Grants Accelerated Approval to Tzield for Newly Diagnosed Pediatric Stage 3 Type 1 Diabetes
Key Dates
What Happened
On June 12, 2026, the FDA granted accelerated approval to a new indication for Tzield (teplizumab), Sanofi's CD3-directed antibody, for pediatric patients ages 8 through 17 who have been recently diagnosed with Stage 3 type 1 diabetes. It is the first FDA-approved treatment aimed at preserving residual beta cell function, delaying the decline of insulin production, after a Stage 3 diagnosis rather than delaying disease onset. The approval rests on the PROTECT trial's effect on C-peptide, a surrogate endpoint reasonably likely to predict clinical benefit, with a required postapproval confirmatory study underway.
Who It Affects
Children and adolescents ages 8 to 17 newly diagnosed with Stage 3 type 1 diabetes. Roughly 64,000 people are diagnosed with type 1 diabetes in the United States each year, per Breakthrough T1D, and clinicians have until now had no disease-modifying option once a child crosses into Stage 3. Tzield was originally approved in November 2022 to delay onset of Stage 3 in Stage 2 patients, and that indication was expanded in April 2026 to children as young as one year old. Sanofi acquired Tzield's developer, Provention Bio, in 2023.
Business Implications
This is an incumbent-pharma move deeper into the pediatric metabolic-care stack. The treatment requires 14 consecutive daily intravenous infusions and carries warnings for cytokine release syndrome and viral reactivation, so health systems will need to build infusion capacity and monitoring protocols before broad uptake, an operational opening for pediatric infusion and care-coordination vendors. Sanofi now holds two teplizumab approvals within the same year covering both pre-symptomatic and newly symptomatic populations, effectively bookending the early course of pediatric type 1 diabetes with one molecule. Pairs with the same-day Dexcom Stelo pediatric CGM clearance as a "diabetes incumbents entering pediatrics" signal.
Sources
Also featured in: The Week in Maternal-Pediatric Health Tech (June 23) — Tuesday Roundup